FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016351279> ?p ?o ?g. }

• W3016351279 endingPage "475" @default.
• W3016351279 startingPage "473" @default.
• W3016351279 abstract "Bullous pemphigoid (BP) is a rare autoimmune bullous disorder caused by IgG autoantibodies against hemidesmosomes at the dermoepidermal junction. BP typically occurs in elderly patients but is rarely reported in infants and children. In infants, associations with infection and vaccinations have been proposed.1Waisbourd-Zinman O. Ben-Amitai D. Cohen A.D. et al.Bullous pemphigoid in infancy: clinical and epidemiologic characteristics.J Am Acad Dermatol. 2008; 58: 41-48Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar,2Baroero L. Coppo P. Bertolino L. Maccario S. Savino F. Three case reports of post immunization and post viral bullous pemphigoid: looking for the right trigger.BMC Pediatr. 2017; 17: 60Crossref PubMed Scopus (23) Google Scholar Topical and systemic steroids are considered first-line treatment options. Disease severity and clinical course vary significantly between patients, and steroid-sparing medications may be necessary.3Schwieger-Briel A. Moellmann C. Mattulat B. et al.Bullous pemphigoid in infants: characteristics, diagnosis and treatment.Orphanet J Rare Dis. 2014; 9: 185Crossref PubMed Scopus (49) Google Scholar,4Watanabe T. Hara S. Muto J. Watanabe D. Akiyama M. Infantile bullous pemphigoid successfully treated with intravenous immunoglobulin therapy.Clin Exp Dermatol. 2017; 42: 576-578Crossref PubMed Scopus (3) Google Scholar A 4-month-old boy with a history of eczema and no vaccinations in the previous 2 months presented with a 25-day history of a pruritic blistering rash. The rash started on the hands and feet and then spread to the back. Physical examination found erythematous, polycyclic papules and plaques on the hands, feet, and back (Fig 1) with no mucosal involvement. There were numerous tense bullae filled with serous fluid on the dorsal and ventral surfaces of the hands and feet (Fig 2).Fig 2Case 1. Tense bullae containing serous fluid on the hand.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Punch biopsy from the abdomen for hematoxylin and eosin found eosinophilic spongiosis, superficial perivascular inflammation, and numerous eosinophils within the papillary tips. A perilesional punch biopsy for direct immunofluorescence showed linear IgG and C3 along the dermoepidermal junction. Enzyme-linked immunosorbent assay of the patient's serum showed BP180 IgG antibody (BP180) greater than 150 U (normal <9) and normal BP230 IgG antibody (BP230) (normal <9). Additionally, indirect immunofluorescence testing of the patient's serum on human salt-split skin substrate showed IgG antibodies along the basement membrane in an epidermal staining pattern. The patient was treated with 3 days of intravenous methylprednisolone and then transitioned to oral prednisone, 1 mg/kg/d. No new blisters were observed at 3-week follow-up, and he tapered off prednisone over 14 weeks. The patient remained free of disease at 9 months. A 2-month-old healthy girl presented with a widespread blistering rash that began on her feet the day after her 2-month vaccinations (DTap, Hib, Rotavirus [RV5], PCV13, and Polio [IPV]). On examination, she had erythematous, edematous, polycyclic plaques distributed over the face, trunk, extremities, hands, and feet (Fig 3), including involvement of both the dorsal and ventral surfaces of the hands and feet. There were numerous overlying tense and ruptured bullae (Fig 4). No mucosal lesions were observed.Fig 4Case 2. Ruptured bullae over a bed of erythematous, edematous, polycyclic plaques on the lower leg and foot.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Skin biopsy for hematoxylin-eosin stain found eosinophilic and neutrophilic spongiosis with small clusters of neutrophils in the papillary dermal tips. Perilesional biopsy for direct immunofluorescence showed linear IgG and C3 along the dermoepidermal junction and weak linear IgA. Serum enzyme-linked immunosorbent assay showed BP180 greater than 100 U and normal BP230. Indirect immunofluorescence performed with the patient's serum showed basement membrane zone IgG antibodies in an epidermal pattern on human salt-split skin substrate. Complete blood count (CBC) was notable for white blood cell (WBC) count of 27.8 K/μL (normal, 6-18 K/μL), platelets of 1,022 K/μL (normal, 150-400 K/μL), and absolute eosinophil count of 4.6 K/μL (normal, 0-0.9 K/μL). She was treated with intravenous methylprednisolone for 3 days followed by oral prednisolone titrated up to 2 mg/kg/d. Given ongoing new lesions, oral erythromycin, 50 mg/kg/d, and niacinamide, 40 mg 3 times daily were added. Three weeks after treatment started, she still had widespread, active disease, so dapsone was added at 0.5 mg/kg/d and titrated up to 1.5 mg/kg/d. The patient continued to have active cutaneous disease, and laboratory values still showed elevated WBCs and platelets with absolute eosinophils increasing to 7.34 K/μL. Three weeks after initiation of dapsone, the patient began to improve. Within days of obtaining disease control, her absolute eosinophil count normalized to 0.01 K/μL with decreases in her WBC and platelet counts. Erythromycin and niacinamide were discontinued. A steroid taper was initiated 3 months later, and a dapsone taper began after another month. A mild flare occurred with an upper respiratory infection, so dapsone was increased back to its prior dose, and erythromycin and niacinamide were restarted. She successfully tapered off systemic steroids while being monitored for adrenal insufficiency 6 months after initial presentation. The inciting factors of infantile BP are not fully understood, but stimulation of the immune system by vaccination has been proposed as a trigger.2Baroero L. Coppo P. Bertolino L. Maccario S. Savino F. Three case reports of post immunization and post viral bullous pemphigoid: looking for the right trigger.BMC Pediatr. 2017; 17: 60Crossref PubMed Scopus (23) Google Scholar,5De La Fuente S. Hernández-Martín Á. De Lucas R. et al.Postvaccination bullous pemphigoid in infancy: report of three new cases and literature review.Pediatr Dermatol. 2013; 30: 741-744Crossref PubMed Scopus (31) Google Scholar As the presented cases and previous literature demonstrate, a history of recent vaccination is not universal, and the time from vaccination to disease manifestation varies greatly. In one study, the clinical characteristics of 81 infantile BP patients were analyzed, and it was determined 25 patients (30.8%) recently received vaccinations with recent being defined as within the previous 4 weeks.3Schwieger-Briel A. Moellmann C. Mattulat B. et al.Bullous pemphigoid in infants: characteristics, diagnosis and treatment.Orphanet J Rare Dis. 2014; 9: 185Crossref PubMed Scopus (49) Google Scholar The number and type of vaccines received varied among patients. In case 2, the patient received vaccinations 1 day before her rash started, which suggests the vaccines may have been a trigger. The presented cases of infantile BP show common clinical and laboratory features of the disease. Both manifested as a blistering rash on acral skin surfaces followed by widespread skin involvement sparing the mucosae. Infantile BP has near-universal involvement of acral sites often followed by a generalized spread and infrequent mucosal involvmement.1Waisbourd-Zinman O. Ben-Amitai D. Cohen A.D. et al.Bullous pemphigoid in infancy: clinical and epidemiologic characteristics.J Am Acad Dermatol. 2008; 58: 41-48Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar The elevated BP180 levels with normal BP230 levels in both cases is representative of infantile BP, which manifests with elevation of BP180 and rarely BP230.3Schwieger-Briel A. Moellmann C. Mattulat B. et al.Bullous pemphigoid in infants: characteristics, diagnosis and treatment.Orphanet J Rare Dis. 2014; 9: 185Crossref PubMed Scopus (49) Google Scholar,6Ferreira B.R. Vaz A.S. Ramos L. Reis J.P. Gonçalo M. Bullous pemphigoid of infancy – report and review of infantile and pediatric bullous pemphigoid.Dermatol Online J. 2017; 23PubMed Google Scholar,7Baykal C. Okan G. Sarica R. Childhood bullous pemphigoid developed after the first vaccination.J Am Acad Dermatol. 2001; 44: 348-350Abstract Full Text Full Text PDF PubMed Scopus (75) Google Scholar The patient in case 2 showed prominent and persistent eosinophilia on her CBC that only decreased once she stopped getting new skin lesions. Previous case reports similarly show eosinophilia on CBC, suggesting eosinophil counts as a possible marker for disease activity and treatment response.6Ferreira B.R. Vaz A.S. Ramos L. Reis J.P. Gonçalo M. Bullous pemphigoid of infancy – report and review of infantile and pediatric bullous pemphigoid.Dermatol Online J. 2017; 23PubMed Google Scholar These cases show differing responses to initial corticosteroid treatment. The patient in case 1 responded quickly, whereas the patient in case 2 required a longer course of corticosteroids and additional steroid-sparing agents. Most infantile BP cases respond quickly to systemic corticosteroids, but dapsone is often given with systemic corticosteroids in refractory cases.1Waisbourd-Zinman O. Ben-Amitai D. Cohen A.D. et al.Bullous pemphigoid in infancy: clinical and epidemiologic characteristics.J Am Acad Dermatol. 2008; 58: 41-48Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar,3Schwieger-Briel A. Moellmann C. Mattulat B. et al.Bullous pemphigoid in infants: characteristics, diagnosis and treatment.Orphanet J Rare Dis. 2014; 9: 185Crossref PubMed Scopus (49) Google Scholar,8Thomsen K. Deleuran M. Vestergaard C. Holm M. Riber-Hansen R. Bech R. Severe infantile bullous pemphigoid treated with dapsone after bridging with systemic glucocorticoid.Case Rep Dermatol. 2019; 11: 187-193Crossref PubMed Scopus (4) Google Scholar intravenous immunoglobulin may also be considered in infantile BP treatment, especially in recalcitrant disease.4Watanabe T. Hara S. Muto J. Watanabe D. Akiyama M. Infantile bullous pemphigoid successfully treated with intravenous immunoglobulin therapy.Clin Exp Dermatol. 2017; 42: 576-578Crossref PubMed Scopus (3) Google Scholar,9Tekin B. Yücelten A.D. Infantile bullous pemphigoid treated using intravenous immunoglobulin: case report and review of the literature.Pediatr Dermatol. 2015; 32: 723-726Crossref PubMed Scopus (14) Google Scholar,10Sugawara N. Nagai Y. Matsushima Y. Aoyama K. Ishikawa O. Infantile bullous pemphigoid treated with intravenous immunoglobulin therapy.J Am Acad Dermatol. 2007; 57: 1084-1089Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar Although infantile BP is considered a rare disease, its incidence has been growing. Whether this is caused by increased disease incidence or better diagnostic techniques is uncertain, but clearly defined diagnostic and treatment guidelines would aid clinicians in identifying and treating patients.1Waisbourd-Zinman O. Ben-Amitai D. Cohen A.D. et al.Bullous pemphigoid in infancy: clinical and epidemiologic characteristics.J Am Acad Dermatol. 2008; 58: 41-48Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar" @default.
• W3016351279 created "2020-04-24" @default.
• W3016351279 creator A5002111818 @default.
• W3016351279 creator A5007682670 @default.
• W3016351279 creator A5067248173 @default.
• W3016351279 date "2020-06-01" @default.
• W3016351279 modified "2023-09-27" @default.
• W3016351279 title "Two infants with blistering rashes originating on acral sites as a presenting sign of infantile bullous pemphigoid" @default.
• W3016351279 cites W1982846034 @default.
• W3016351279 cites W2062006031 @default.
• W3016351279 cites W2063339486 @default.
• W3016351279 cites W2114104405 @default.
• W3016351279 cites W2153592226 @default.
• W3016351279 cites W2159974752 @default.
• W3016351279 cites W2590368505 @default.
• W3016351279 cites W2592689548 @default.
• W3016351279 cites W2620035803 @default.
• W3016351279 cites W2955299124 @default.
• W3016351279 doi "https://doi.org/10.1016/j.jdcr.2020.04.006" @default.
• W3016351279 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7256229" @default.
• W3016351279 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32490102" @default.
• W3016351279 hasPublicationYear "2020" @default.
• W3016351279 type Work @default.
• W3016351279 sameAs 3016351279 @default.
• W3016351279 citedByCount "1" @default.
• W3016351279 countsByYear W30163512792020 @default.
• W3016351279 crossrefType "journal-article" @default.
• W3016351279 hasAuthorship W3016351279A5002111818 @default.
• W3016351279 hasAuthorship W3016351279A5007682670 @default.
• W3016351279 hasAuthorship W3016351279A5067248173 @default.
• W3016351279 hasBestOaLocation W30163512791 @default.
• W3016351279 hasConcept C134306372 @default.
• W3016351279 hasConcept C139676723 @default.
• W3016351279 hasConcept C159654299 @default.
• W3016351279 hasConcept C16005928 @default.
• W3016351279 hasConcept C203014093 @default.
• W3016351279 hasConcept C2779252107 @default.
• W3016351279 hasConcept C33923547 @default.
• W3016351279 hasConcept C71924100 @default.
• W3016351279 hasConceptScore W3016351279C134306372 @default.
• W3016351279 hasConceptScore W3016351279C139676723 @default.
• W3016351279 hasConceptScore W3016351279C159654299 @default.
• W3016351279 hasConceptScore W3016351279C16005928 @default.
• W3016351279 hasConceptScore W3016351279C203014093 @default.
• W3016351279 hasConceptScore W3016351279C2779252107 @default.
• W3016351279 hasConceptScore W3016351279C33923547 @default.
• W3016351279 hasConceptScore W3016351279C71924100 @default.
• W3016351279 hasIssue "6" @default.
• W3016351279 hasLocation W30163512791 @default.
• W3016351279 hasLocation W30163512792 @default.
• W3016351279 hasLocation W30163512793 @default.
• W3016351279 hasLocation W30163512794 @default.
• W3016351279 hasOpenAccess W3016351279 @default.
• W3016351279 hasPrimaryLocation W30163512791 @default.
• W3016351279 hasRelatedWork W1598341254 @default.
• W3016351279 hasRelatedWork W2064063214 @default.
• W3016351279 hasRelatedWork W207790567 @default.
• W3016351279 hasRelatedWork W2082488334 @default.
• W3016351279 hasRelatedWork W2135228719 @default.
• W3016351279 hasRelatedWork W2158189544 @default.
• W3016351279 hasRelatedWork W2558183717 @default.
• W3016351279 hasRelatedWork W2904445328 @default.
• W3016351279 hasRelatedWork W3016351279 @default.
• W3016351279 hasRelatedWork W345074830 @default.
• W3016351279 hasVolume "6" @default.
• W3016351279 isParatext "false" @default.
• W3016351279 isRetracted "false" @default.
• W3016351279 magId "3016351279" @default.
• W3016351279 workType "article" @default.